The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

Endocrine Reviews

Volumn 9, Issue 4, 1988, Pages 417-436

  Lamberts, Steven W J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOHYPOPHYSIS HORMONE; CORTICOTROPIN; DRUG DERIVATIVE; GONADOTROPIN; GROWTH HORMONE; PROLACTIN; SOMATOSTATIN; THYROTROPIN;

ADENOHYPOPHYSIS; HUMAN; HYPOPHYSIS TUMOR; PHYSIOLOGY; REVIEW;

CORTICOTROPIN; GONADOTROPINS, PITUITARY; GROWTH HORMONE; HUMAN; PITUITARY GLAND, ANTERIOR; PITUITARY HORMONES, ANTERIOR; PITUITARY NEOPLASMS; PROLACTIN; SOMATOSTATIN; THYROTROPIN;

EID: 0024117485     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/edrv-9-4-417     Document Type: Article

References (199)

1. Krulich I, Dhariwal APS, McCann SM 1968 Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83:783
2. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77
3. Brazeau P 1986 Somatostatin: a peptide with unexpected physiologic activities. Am J Med 81 [Suppl 6B]:8
4. Vale W, Brazeau P, Rivier C 1975 Somatostatin. Recent Prog Horm Res 31:365
5. Guillemin R, Gerich JE 1976 Somatostatin: physiological and clinical significance. Annu Rev Med 18:173
6. Gerich JE, Raptis S, Rosenthal J 1978 Somatostatin symposium. Metabolism 28:1129
7. Reichlin S 1983 Somatostatin. N Engl J Med 309:1495
8. Gomez-Pan A, Rodrigueze-Arnao MD 1983 Somatostatin and growth hormone releasing factor: synthesis, location, metabolism and function. Clin Endocrinol Metab 12:469
9. Raptis S, Rosenthal J, Gerich JE 1984 Program of the Second International Symposium on Somatostatin. Attempto Verlag, Tubingen, Germany, p 1
10. Patel JC, Tannenbaum GS 1985 Somatostatin. Plenum Press, New York
11. Patel YC, Srikant CB 1986 Somatostatin mediation of adenohypophysial secretion. Annu Rev Physiol 48:551
12. Reichlin S 1987 Somatostatin. Basic and Clinical Status. Plenum Press, New York, p 1
13. Guillemin R 1978 Peptides in the brain: the new endocrinology of the neuron. Science 202:390
14. Besser GM, Mortimer CH, McNeilly AS, Thorner MO, Batistoni GA, Bloom SR, Kastrup KW, Hanssen KF, Hall R, Coy DH, Kastin AJ, Schally AV 1974 Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones. Br Med J 4:622
15. Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Tunbridge WMG, Thorner MO, Hall R 1974 Growth hormone release inhibiting hormone in acromegaly. Br Med J 1:274
16. Pless J, Bauer W, Briner U, Doepfner W, Marbach P, Maurer R, Petcher TJ, Reubi J-C, Vonderscher J 1986 Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 21 [Suppl 119]:54
17. Nutt RF, Colton CD, Saperstein R, Veber DF 1987 Side chain conformations of somatostatin analogs when bound to receptors. Plenum Press, New York, p 83
18. Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV 1986 Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sei USA 83:1896
19. Gottesman I, Tobert J, Vandlen R, Gerich J 1986 Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L363, 586) in insulin-dependent diabetes mellitus. Life Sei 38:2211
20. Gulya K, Pelton JT, Hruby VJ, Yamamura HI 1986 Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward MU opioid receptors. Life Sci 38:2221
21. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133
22. del Pozo E, Neufeld M, Schlutter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nuesch E, Marbach P, Cramer H, Kerp L 1986 Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh) 111:433
23. Williams G, Ball JA, Burrin JM, Joplin GF, Bloom SR 1986 Effective and lasting growth hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet 2:774
24. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E 1985 The mini-somatostatin SMS 201-995 induces long-acting inhibition of GH secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161
25. Tannenbaum GS 1987 Physiological significance of somatostatin in growth hormone secretion. In: Reichlin S (ed) Somatostatin, Basic and Clinical Status. Plenum Press, New York, p 169
26. Tannenbaum GS 1987 Interactions of growth hormone-releasing factor and somatostatin in regulation of the rhythmic secretion of growth hormone. In: Ludecke DK, Tolis G (eds) Growth Hormone, Growth Factors and Acromegaly. Raven Press, New York, p 37
27. Tannenbaum GS, Ling N 1984 The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 115:1952
28. Plotsky PM, Vale W 1985 Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science 230:461
29. Vance ML, Kaiser DL, Evans WS, Furlanetto R, Vale W, Rivier J, Thorner MO 1985 Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. J Clin Invest 75:1584
30. Brazeau P, Ling N, Bohlen P, Esch F, Ying SY, Guillemin R 1982 Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci USA 79:7909
31. Vale W, Vaughan J, Yamatomo G, Spiess J, Rivier J 1983 Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro. Endocrinology 112:1553
32. Lamberts SWJ, Oosterom R 1985 The regulation of growth hormone secretion. Studies on the interaction of growth hormonereleasing factor and somatostatin at the pituitary level. Front Horm Res 14:137
33. Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly AS, Mortimer CH, Turnbridge WMG, Phenekos C, Weightman D 1973 Actions of growth hormone-release inhibiting in health men in acromegaly. Lancet 2:581
34. Prange-Hansen A, Orskov H, Seyer-Hansen K, Lundbaek K 1973 Some actions of growth hormone-release inhibiting factor. Br Med J 3:522
35. Siler TM, Vanderberg G, Yen SSC, Brazeau P, Vale W, Guillemin R 1973 Inhibition of growth hormone release in humans by somatostatin. J Clin Endocrinol Metab 37:632
36. Parker DC, Rossman LG, Siler TM 1974 Inhibition of the sleeprelated peak in physiological human growth hormone release by somatostatin. J Clin Endocrinol Metab 38:496
37. Wehrenberg WB, Ling N, Bohlen P, Esch F, Brazeau P, Guillemin R 1982 Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion. Biochem Bioph Res Commun 109:562
38. Davies RR, Turner SJ, Orskov H, Johnston DG 1985 The interaction of human pancreatic growth hormone releasing factor 1-44 with somatostatin in vivo in normal man. Clin Endocrinol (Oxf) 23:271
39. Losa M, Muller OA, Sobieszczyks, von Werder K 1985 Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects. Clin Endocrinol (Oxf) 23:715
40. Brazeau P, Bohlen P, Guillemin R, Mechanism of the antagonism between growth hormone releasing factor (GRF) and somatostatin on the release of pituitary growth hormone. Program of the 64th Annual Meeting of The Endocrine Society, San Francisco, CA, 1982 (Abstract 539)
41. Fukata J, Diamond DJ, Martin JB 1985 Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells. Endocrinology 117:457
42. Lamberts SWJ, Verleun T, Zuiderwijk JM, Oosterom R 1987 The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion. Acta Endocrinol (Copenh) 115:196
43. Fukata J, Martin JB 1986 Influence of sex steroid hormones on rat growth hormone-releasing factor and somatostatin in dispersed pituitary cells. Endocrinology 119:2256
44. Schonbrunn A 1982 Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 110:1147
45. Mulchahey JJ, Di Blasio AM, Jaffe RB 1988 Effects of growth hormone (GH)-releasing hormone and somatostatin on GH secretion from individual human and monkey fetal anterior pituitary cells: modulation by thyroid hormones and glucocorticoids. J Clin Endocrinol Metab 66:395
46. Richman RA, Weiss JP, Hochberg Z, Florini JR 1981 Regulation of growth hormone release: evidence against negative feedback in rat pituitary cells. Endocrinology 108:2287
47. Chihara K, Minamitani N, Kaji H, Arimura A, Fujita T 1981 Intraventricularly injected growth hormone stimulates somatostatin release into rat hypophysial portal blood. Endocrinology 109:2279
48. Conway S, McCann SM, Krulich L 1985 On the mechanism of growth hormone autofeedback regulation: possible role of somatostatin and growth hormone-releasing factor. Endocrinology 117:2284
49. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L 1981 Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212:1279
50. Goodyer CG, De Stephano L, Guyda HJ, Posner BJ 1984 Effects of insulin-like growth factors on adult male rat pituitary function in tissue culture. Endocrinology 115:1568
51. Yamashita S, Melmed S 1986 Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 118:176
52. Ceda GP, Davis RG, Rosenfeld RG, Hoffman AR 1987 The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II. Endocrinology 120:1658
53. Goodyer CG, DeStephano L, Lei WH, Guyda HJ, Posner BI 1984 Characterization of insulin-like growth factor receptors in rat anterior pituitary hypothalamus and brain. Endocrinology 114:1187
54. Rosenfeld RG, Ceda G, Wilson DM, Dollar LA, Hoffman AR 1985 Insulin and insulin-like growth factor (somatomedin) receptors on cloned rat pituitary tumor cells. Endocrinology 114:1571
55. Yamashita S, Melmed S 1987 Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest 79:449
56. Morita S, Yamashita S, Melmed S 1987 Insulin-like growth factor I action on rat anterior pituitary cells: effects on intracellular and messenger ribonucleic acid levels. Endocrinology 121:2000
57. Hoeffler JP, Hicks SA, Frawley LS 1987 Existence of somatotrope subpopulations which are differentially responsive to insulin-like growth factor I and somatostatin. Endocrinology 120:1936
58. Lamberts SWJ, den Holder F, Hofland LJ, The interrelationship between the effects of insulin-like growth factor I and somatostatin on growth hormone secretion by normal rat pituitary cells. The role of glucocorticoids Endocrinology, in press
59. Lumpkin MD, Negro-Villar A, McCann SM 1981 Paradoxical elevation of growth hormone by intraventricular somatostatin: possible ultra-short-loop feedback. Science 211:1072
60. Peterfreund RA, Vale WW 1984 Somatostatin analogs inhibit somatostatin secretion from cultured hypothalamic cells. Neuroendocrinology 39:397
61. Tannenbaum GS, Patel YC 1986 On the fate of centrally administered somatostatin in the rat: massive hypersomatostatinemia resulting from leakage into the peripheral circulation has effects on growth hormone secretion and glucoregulation. Endocrinology 118:2137
62. Schonbrunn A, Koch BD 1987 Mechanism by which somatostatin inhibits pituitary hormone release. In: Reichlin S (ed) Somatostatin. Basic and Clinical Status. Plenum Press, New York, p 121
63. Melmed S, Yamashita S, Pixley S 1987 Human growth hormone gene regulation in somatotroph cell cultures. In:Robbins RJ, Melmed S (eds) Acromegaly. A Century of Scientific and Clinical Progress. Plenum Press, New York, p 17
64. Robbins RJ 1987 In: Reichlin S (ed) Somatostatin: Basic and Clinical Status. Plenum Press, New York, p 149
65. Adams EF, Winslow CKJ, Mashiter K 1983 Pancreatic growth hormone releasing factor stimulates growth hormone secretion by pituitary cells. Lancet 1:1100
66. Webb CB, Thominet JL, Frohman LA 1983 Ectopic growth hormone releasing factor stimulates growth hormone release from human somatotroph adenomas in vitro. J Clin Endocrinol Metab 56:417
67. Lamberts SWJ, Verleun T, Oosterom R 1984 The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly. J Clin Endocrinol Metab 58:250
68. Adams EF, Bhuttacharji SC, Halliwell CLJ, Lotzou M, Birch G, Mashiter K 1984 Effect of pancreatic growth hormone releasing factors on GH secretion by human somatotrophic pituitary tumors in cell culture. Clin Endocrinol (Oxf) 21:709
69. Oosterom R, Verleun T, Lamberts SWJ 1984 Human growth hormone-secreting pituitary adenoma cells in long-term culture: effects of dexamethasone and growth hormone releasing factor. J Endocrinol 100:353
70. Ishibashi M, Yamaji T 1985 Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture. J Clin Endocrinol Metab 60:985
71. White MC, Daniels M, Kendall-Taylor P, Turner SJ, Mathias D, Teasdale G 1985 Effects of growth hormone-releasing factor (144) on growth hormone release from human somatotrophinomas in vitro: interaction with somatostatin, dopamine, vasoactive intestinal peptide and cycloheximide. J Endocrinol 105:269
72. Ikuyama S, Nawata H, Kato KI, Natori S, Ibayashi H 1987 Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin. J Clin Endocrinol Metab 64:572
73. Serri O 1987 Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion. Clin Endocrinol (Oxf) 27:675
74. Ceda GP, Hoffman AR, Silverberg GD, Wilson DM, Rosenfeld RG 1985 Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. J Clin Endocrinol Metab 60:1204
75. Yamashita S, Weiss M, Melmed S 1986 Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells. J Clin Endocrinol Metab 63:730
76. Melmed S, Braunstein D, Horvath E, Ezrin C, Kovacs K 1983 Pathophysiology of acromegaly. Endocr Rev 4:271
77. Ishibashi M, Yamaji T 1984 Direct effects of catecholamine, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. J Clin Invest 73:66
78. Beck-Peccoz P, Piscitelli G, Amr S, Ballabio M, Bassetti M, Giannattasio G, Spada A, Nissim M, Weintraub BD, Faglia G Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and a-subunit: evidence for secretion of TSH with increased bioactivity. J Clin Endocrinol Metab 62:704
79. White MC, Newland P, Daniels M, Turner SJ, Mathias D, Teasdale G, Kendall-Taylor P 1986 Growth hormone secreting pituitary adenomas are heterogeneous in cell culture and commonly secrete glycoprotein hormone a-subunit. Clin Endocrinol (Oxf) 25:173
80. Ishibashi M, Yamaji T, Takaku F, Teramoto A, Fukushima T Secretion of glycoprotein hormone a-subunit by pituitary tumors. J Clin Endocrinol Metab 64:1187
81. Lamberts SWJ, Verleun T, Hofland L, del Pozo E 1987 A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumor cells of acromegalic patients. Clin Endocrinol (Oxf) 27:11
82. Reubi JC, Perrin M, Rivier J, Vale W 1982 High affinity binding sites for somatostatin to rat pituitary. Biochem Biophys Res Commun 105:1538
83. Enjalbert A, Tapia-Arancipia L, Rieutort M, Brazeau P, Kordon C, Epelbaum J 1982 Somatostatin receptors on rat anterior pituitary membranes. Endocrinology 110:1634
84. Aguilera G, Parker DS 1982 Pituitary somatostatin receptors. J Biol Chem 257:1134
85. Leitner JW, Rifkin RM, Maman A, Sussman KE 1979 Somatostatin binding to pituitary plasma membranes. Biochem Biophys Res Commun 87:919
86. Reubi JC, Perrin M, Rivier J, Vale W 1982 Pituitary somatostatin receptors: dissociation at the pituitary level of receptor affinity and biological activity for selective somatostatin analogs. Regul Pept 4:141
87. Schonbrunn A, Rorstad OP, Westendorf JM, Martin JB 1983 Somatostatin analogs: correlation between receptor binding affinity and biological potency in GH pituitary cells. Endocrinology 113:1135
88. Reubi JC, Landolt AM 1984 High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 59:1148
89. Moyse E, Le Dafniet M, Epelbaum J, Pagesy P, Peillon F, Kordon C, Enjalbert A 1985 Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. J Clin Endocrinol Metab 61:98
90. Ikuyama S, Nawata H, Kato K, Karashima T, Ibayashi H, Nakagaki H 1985 Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 6:666
91. Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H 1986 Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocrinol Metab 62:729
92. Reubi JC, Heitz PU, Landolt AM 1987 Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 65:65
93. Yen SSC, Siler TM, DeVane GW 1974 Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. N Engl J Med 290:935
94. Dunn PJ, Donald RA, Espiner EA 1976 A comparison on the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly. Clin Endocrinol (Oxf) 5:167
95. Gomez-Pan A, Turnbridge WMC, Duns A 1975 Hypothalamic hormone interaction in acromegaly. Clin Endocrinol (Oxf) 4:455
96. Lamberts SWJ, del Pozo E 1986 Acute and long-term effects of SMS 201-995 in acromegaly. Scand J Gastroenterol 21 [Suppl 119]:141
97. Plewe G, Krause U, Beyer J, Neufeld M, del Pozo E 1984 Longacting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1:782
98. Ch’ng LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR 1985 Long term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 290:284
99. Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E 1985 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576
100. Plewe G, Schrezenmeir J, Nolken G, Krause U, Beyer J, Kasper H, del Pozo E 1986 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 over 6 months. Klin Wochenschr 64:389
101. Barnard LB, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IMD 1986 Treatment of resistant acromegaly with a longacting somatostatin analogue (SMS 201-995). Ann Intern Med 105:856
102. Jackson I, Barnard LB, Lamberton P 1986 Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 81 [Suppl 6B]:94
103. Oppizzi G, Petroncini MM, Dallabonzana D, Cozzi R, Verde G, Chiodini PG, Liuzzi A 1986 Relationship between somatomedinC and growth hormone levels in acromegaly: basal and dynamic evaluation. J Clin Endocrinol Metab 63:1348
104. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E 1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 64:447
105. Pieters GFFM, van Liessum PA, Smals AGH, van Gennep JA, Benraad ThJ, Kloppenborg PWC 1987 Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth responses. Acta Endocrinol (Copenh) 116 [Suppl 286]:9
106. Lamberts SWJ, Uitterlinden P, del Pozo E 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65:703
107. Comi RJ, Gorden P 1987 The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 64:37
108. George SR, Hegele RA, Burrow GN 1987 The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. Clin Invest Med 10:309
109. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ 1988 Treatment of acromegaly with the long-acting somatostatin analog SMS 201995. J Clin Endocrinol Metab 66:16
110. Lamberts SWJ, Uitterlinden P, Schuijff PC, Klijn JGM, Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical “cure.” Clin Endocrinol (Oxf), in press
111. Harris AG, Prestele H, Herold K, Efficacy of SMS 201-995 (Sandostatin) in 178 acromegalic patients. In: Lamberts SWJ (ed) Treatment of Acromegaly with Sandostatin. JF Bergmann, Miinchen, in press
112. Christensen SE, Weeke J, Orskov H, Mpller A, Flyvbjerg A, Harris AG, Lund E, Joorgensen J 1987 Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxf) 27:297
113. Ducasse MCR, Tauber JP, Tourre A, Bonafe A, Babin T, Tauber MT, Harris AG, Bayard F 1987 Shrinking of a growth hormoneproducing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 65:1042
114. Timsit J, Chanson P, Larger E, Duet M, Mosse A, Guillausseau PJ, Harris AG, Moulonguet M, Warnet A, Lubetzki J 1987 The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Acta endocrinol (Copenh) 116:108
115. Lamberts SWJ, Uitterlinden P, Verleun T 1987 Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201-995). Eur J Clin Invest 17:354
116. Daughaday WH, Hall K, Salmon WD, Van den Brande JL, Van Wyk JJ 1987 On the nomenclature of the Somatomedins and insulin-like growth factors. J Clin Endocrinol Metab 65:1075
117. Pieters GFFM, Smals AGH, Kloppenborg PWC 1986 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 314:1391
118. Zadik ZVI, Chalew SA, McCarter RJ, Meistas M, Kowarski AA 1985 The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 60:513
119. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Heilman L 1972 Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 35:665
120. Drobny EC, Amburn K, Baumann G 1983 Circadian variation of basal plasma growth hormone in man. J Clin Endocrinol 57:524
121. Florini, J, Printz P, Vitiello M, Hintz R 1985 Somatomedin-C levels in healthy young and old men: relationship to peak and 24hour integrated levels of growth hormone. J Gerontol 40:2
122. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64:51
123. Lamberts SWJ, Zweens M, Verschoor L, del Pozo E 1986 A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 63:16
124. Oppizzi G, Botalla L, Verde G, Cozzi R, Liuzzi A, Chiodini PG 1980 Homogeneity in the growth hormone-lowering effect of dopamine and somatostatin in acromegaly. J Clin Endocrinol Metab 51:616
125. Hanew K, Kokubun M, Sasaki A, Mouri T, Yoshinaga K 1980 The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. J Clin Endocrinol Metab 51:292
126. Pieters GFFM, Romeijn JE, Smals AGH, Kloppenborg PWC 1982 Somatostatin sensitivity and growth hormone responses to releasing hormones and bromocryptine in acromegaly. J Clin Endocrinol Metab 54:942
127. Lamberts SWJ, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ 1985 Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GHJ prolactin-containing pituitary adenomas. J Clin Endocrinol Metab 60:1148
128. Lamberts SWJ, Klijn JGM, Kwa GH, Birkenhager JC 1979 The dynamics of growth hormone and prolactin secretion in acromegalic patients with “mixed” pituitary tumors. Acta Endocrinol (Copenh) 90:198
129. Lamberts SWJ, Liuzzi A, Chiodini PG, Verde S, Klijn JGM, Birkenhager JC 1982 The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 12:151
130. Lamberts SWJ, Zweens M, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ, del Pozo E 1986 The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 25:201
131. Lamberts SWJ 1984 Antimitotic actions of dopaminergic drugs on human pituitary tumors. Neuroendocr Perspect 3:317
132. Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Tonon C 1984 Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab 58:988
133. Wilson DM, Hoffman AR 1986 Reduction of pituitary size by the somatostatin analogue SMS 201-995 in a patient with an islet cell tumor secreting growth hormone releasing factor. Acta Endocrinol (Copenh) 113:23
134. Spinas GA, Zaph J, Landolt AM, Stuckmann G, Froesch ER 1987 Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh) 114:249
135. Landolt AM 1984 Effects of bromocriptine on prolactinoma morphology. In: Black PM, Zervas NT, Ridgway EC, Martin JB (eds) Secretory Tumors of the Pituitary Gland. Raven Press, New York, p 82
136. Beckers A, Stevenaert A, Howarth E, Kovacs K, Hennen G, The treatment of acromegaly with SMS 201-995. In: Landolt A (ed) Proceedings of the Fourth European Workshop on Pituitary Adenomas. Plenum Press, New York, in press
137. Landolt AM, Osterwalder V, Jantzer R, Stuckmann G 1985 Preoperative treatment of acromegaly with SMS 201-995: surgical and pathological observations. Neuro Endocrinol Lett 7:94
138. George SR, Kovacs K, Asa SL, Horvath E, Cross EG, Burrow GN Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol (Oxf) 26:395
139. Vale W, Rivier C, Brazeau P, Guillemin R 1974 Effects of somatostatin on the secretion of thyrotropin and prolactin. Endocrinology 95:968
140. Drouin J, de Lean A, Rainville D, Lachance R, Labrie F 1976 Characteristics of the interaction between thyrotropin-releasing hormone and somatostatin for thyrotropin and prolactin release. Endocrinology 98:514
141. Hirooka Y, Hollander CS, Suzuki S, Ferdinand P, Juan SI 1978 Somatostatin inhibits release of thyrotropin releasing factor from organ cultures of rat hypothalamus. Proc Natl Acad Sei USA 75:4509
142. Arimura A, Schally AV 1976 Increase in basal and thyrotropin releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats. Endocrinology 98:1069
143. Ferland L, Labrie F, Jobin M, Arimura A, Schally AV 1976 Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun 68:149
144. Belanger A, Labrie F, Borgeat P, Savary M, Cote J, Drouin J, Schally AV, Coy DH, Sestanj K, Nelson V, Gotz M, Immer H 1974 Inhibition of growth hormone and thyrotropin release by growth hormone-release inhibiting hormone. Mol Cell Endocrinol 1:329
145. Lamberts SWJ, Zuyderwijk J, den Holder F, van Koetsveld P, Hofland L, Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin in release by cultured rat pituitary cells. Neuroendocrinology, in press
146. Siler TM, Yen SSC, Vale W, Guillemin R 1974 Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 38:742
147. Skamene A, Patel YL 1984 Infusion of graded concentrations of somatostatin in man: pharmacokinetics and differential inhibitory effects on pituitary and islet hormones. Clin Endocrinol (Oxf) 20:555
148. Williams TC, Kelijman M, Crelin WC, Downs TR, Frohman LA Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man. J Clin Endocrinol Metab 66:39
149. Davies RR, Miller M, Turner SJ, Goodshop THJ, Cook DB, Watson M, McGill A, Orskov H, Alberti KGMM, Johnston DC 1986 Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol (Oxf) 24:665
150. Root AW, Snyder PJ, Rezvani I, Di George AM, Utiger RD 1973 Inhibition of thyrotropin-releasing hormone-mediated secretion of thyrotropin by human growth hormone. J Clin Endocrinol Metab 36:103
151. Lippe BM, Van Herle AJ, La Franchi SH, Uller RP, Lavin N, Kaplan S 1975 Reversible hypothyroidism in growth hormonedeficient children treated with human growth hormone. J Clin Endocrinol Metab 40:612
152. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG 1986 Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663
153. Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O’Connel MJ, Hahn RG 1987 Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107:162
154. Smallridge RC, Col MC 1987 Thyrotropin-secreting pituitary tumors. Clin Endocrinol Metab 16:765
155. Rechini E, Giustina G, Cantalamessa L, Perachi M 1976 Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: study with somatostatin. J Clin Endocrinol Metab 43:924
156. Lamberg BA, Pelkonen F, Gordin A 1978 TSH-induced hyperthyroidism and acromegaly due to pituitary tumor. Ann Endocrinol (Paris) 39:14A (Abstract)
157. Spada A, Bassetti M, Martino E, Faglia G 1985 In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma: effects of somatostatin and dopamine. J Endocrinol Invest 8:193
158. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD 1986 Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317:12
159. Guillasseau PJ, Chanson P, Timsit J, Warnet A, Lajeunie E, Duet M, Lubetski J 1987 Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting pituitary adenoma. N Engl J Med 317:53
160. Smallridge RC, Ahmann AJ, Fein HG, Long-term control of a TSH-secreting macroadenoma with a somatostatin analogue (SMS 201-995). Program of the Sixty-Second Annual Meeting of the American Thyroid Association, Washington, DC, 1987, p 16
161. Wemeau JL, Dewailly D, Leroy R, D’Herbomez M, Mazzuca M, Decoulx M, Jaquet P 1988 Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropinand growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 66:636
162. Weintraub BD, Gershergorn MC, Kourides IA, Fein H 1981 Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med 95:339
163. Refetoff S 1982 Syndrome of thyroid hormone resistance. Am J Physiol 243:E88
164. Williams G, Kraenzlin M, Sandler L, Burrin J, Law A, Bloom S, Joplin GF 1986 Hyperthyroidism due to nontumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995) Acta Endocrinol (Copenh) 113:42
165. Brown MR, Rivier C, Value W 1984 Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 114:1546
166. Kraicer J, Gajewski TC, Moor BC 1984 Release of pro-opiomelanocortin-derived peptides from the pars intermediate and pars distalis of the rat pituitary: effect of corticotrophin-releasing factor and somatostatin. Neuroendocrinology 41:363
167. Voight KH, Fehm HL, Lang RE, Walter R 1977 The effect of somatostatin and of prolyl-leucyl-glycinamide (MIF) on ACTH release in dispersed pituitary cells. Life Sci 21:739
168. Nicholson SA, Adrian TE, Gillham B, Jones MT, Bloom SR 1984 Effect of hypothalamic neuropeptides on corticotrophin release from quarters of rat anterior pituitary gland in vitro. J. Endocrinol 100:219
169. Lightman SL, Fox P, Dunne MJ 1986 The effect of SMS 201995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol [Suppl] 119:84
170. Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF 1976 Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 54:173
171. Richardson UI, Schonbrunn A 1981 Inhibition of adrenocorticotropin secretion somatostatin in pituitary cells in culture. Endocrinology 108:281
172. Heisler S, Reisine TD, Hook VYH, Axelrod J 1982 Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci USA 79:6502
173. Lamberts SWJ, Reubi JC, Uitterlinden P, Zuiderwijk J, van den Werff P, van Hal P 1986 Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the growth of the prolactinJ adrenocorticotropinsecreting pituitary tumor 7315a. Endocrinology 118:2188
174. Lamberts SWJ, Uitterlinden P, Klijn JGM 1988 The effect of the long-acting somatostatin analog SMS 201-995 on ACTH secretion in Nelson’s syndrome and Cushing’s disease. Program of the Eighth International Congress of Endocrinology, Kyoto, Japan, 1988, Abstract S-196
175. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH 1975 Inhibition by somatostatin on ACTH secretion in Nelson’s syndrome. J Clin Endocrinol Metab 40:1125
176. Benker G, Hackenberg K, Hamburger B, Reinwein D 1976 Effects of grown hormone release-inhibiting hormone and bromocriptine (CB 154) in states of abnormal pituitary-adrenal function. Clin Endocrinol (Oxf) 5:187
177. Nelson DH, Meakin JW, Thorn GW 1960 ACTH-producting pituitary tumors following adrenalectomy for Cushing’s syndrome. Ann Intern Med 52:560
178. Lamberts SWJ, Tilanus HW, Klooswijk AIJ, Braining HA, van der Lely AJ, de Jong FH, Successful treatment with SMS 201995 of Cushing’s syndrome caused by ectopic ACTH secretion from a metastasized gastrin-secreting pancreatic islet cell carcinoma. J Clin Endocrinol Metab, in press
179. Maurer R, Reubi JC 1986 Somatostatin receptors in the adrenal. Mol Cell Endocrinol 45:81
180. Hanew K, Rennels EG 1982 Effects of culture age on PRL and GH responses to bromocriptine and somatostatin from pituitary cultures of rat anterior pituitary cells. Proc Soc Exp Biol Med 171:112
181. Labrie F, Drouin J, Ferland L, Lagace L, Beaulieu M, De Lean A, Kelly PA, Caron MG, Raymond V 1978 Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. Recent Prog Horm Res 34:25
182. Kimura N, Hayafuji C, Konagaya H, Takahashi K 1986 17βestradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119:1028
183. Hofland LJ, van Koetsveld P, Koper JW, den Holder A, Lamberts SWJ 1987 Weak estrogenic activity of phenol red in the culture medium: its role in the study of the regulation of prolactin release in vitro. Mole Cell Endocrinol 54:43
184. Raymond V, Beaulieu M, Labrie F, Boissier J 1978 Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173
185. Cooper GR, Shin SH 1981 Somatostatin inhibits prolactin secretion in the estradiol primed male rat. Can J Physiol Pharmacol 59:1082
186. Saunders SL, Reifel CW, Shin SH 1983 Ultrastructural changes rapidly induced by somatostatin may inhibit prolactin release in estrogen-primed rat adenohypophysis. Cell Tissue Res 232:21
187. Karashima T, Schally A 1987 Inhibitory effects of somatostatin analogs on prolactin secretin in rats pretreated with estrogen or haloperidol (42518). Proc Soc Exp Biol Med 185:69
188. Copinschi G, Leclercq-Meyer V, Virasoro E, l’Hermite, M, Vanhaelst L, Goldstein J, Leclercq R, Fery F, Robyn C 1976 Pituitary and extra-pituitary effects of somatostatin in normal man. Horm Metab Res 8:226
189. Gooren LJG, Harmsen-Louman W, van Kessel H 1984 Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man. J Endocrinol 103:333
190. Doepfner W, Briner U, Marbach P, Rudin M 1986 Regression of oestrogen-induced pituitary hyperplasia after chronic treatment with Sandostatin (SMS 201-995) in the rat. Eur Cancer Clin Oncol 22:749 (Abstract V-3)
191. Saunders SL, Reifel CW, Shin SH 1983 Ultrastructural changes rapidly induced by somatostatin may inhibit prolactin release in estrogen-primed rat adenohypophysis. Cell Tissue Res 232:21
192. Landolt AM, Heitz PH 1986 Alpha-subunit-producing pituitary adenomas. Immunocytochemical and ultrastructural studies. Virchows Arch [Pathol Anat] 409:417
193. Bloom Sr, Polak JM 1980 Glucagonomas, Vipomas and somatostatinomas. Clin Endocrinol Metab 9:285
194. Lamberts SWJ, del Pozo E 1986 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 314:1391
195. Verschoor L, Lamberts SWJ, Uitterlinden P, del Pozo E 1986 Glucose tolerance during long term treatment with a somatostatin analogue. Br Med J 293:1327
196. Reisine T, Axelrod J 1983 Prolonged somatostatin pretreatment desensitizes somatostatin’s inhibition of receptor-mediated release of adrenocorticotropin and densensitizes adenylate cyclase. Endocrinology 113:811
197. Marki F, Bucher UM, Richter JC 1982 Multiple subcutaneous injections of somatostatin induce tachyphylaxis of the suppression of plasma insulin, but not glucagon in the rat. Regul Pept 4:333
198. Consensus meeting on the use of somatostatin analogs in the treatment of acromegaly, In: Lamberts SWJ (ed) The Treatment of Acromegaly with Sandostatin. J. F. Bergmann, Miinchen, in press
199. Epelbaum J, Enjalbert A, Krantic S, Musset F, Bertrand R, Roasolonjanahary R, Shu C, Kordon C 1987 Somatostatin receptors on pituitary somatotrophs, thyrotrophs, and lactotrophs: pharmacological evidence for loose coupling to adenylate cyclase. Endocrinology 121:2177